Targeting tumour-associated macrophages with CCR2 inhibition in combination with FOLFIRINOX in patients with borderline resectable and locally advanced pancreatic cancer: a single-centre, open-label, dose-finding, non-randomised, phase 1b trial
Nywening, Timothy M, Wang-Gillam, Andrea, Sanford, Dominic E, Belt, Brian A, Panni, Roheena Z, Cusworth, Brian M, Toriola, Adetunji T, Nieman, Rebecca K, Worley, Lori A, Yano, Motoyo, Fowler, KathrynLanguage:
english
Journal:
The Lancet Oncology
DOI:
10.1016/S1470-2045(16)00078-4
Date:
April, 2016
File:
PDF, 475 KB
english, 2016